Loading company…
Viridian Therapeutics develops therapies for autoimmune and rare diseases, with a focus on thyroid eye disease.
Viridian Therapeutics, formerly MiRagen Therapeutics, develops therapies for autoimmune and rare diseases using microRNA biology. Its pipeline includes investigational candidates for thyroid eye disease and other autoimmune conditions. The company is based in Waltham, US, and has offices in Massachusetts and Colorado. In January 2024, it raised USD 150 million in a private placement.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign inWork at MiRagen Therapeutics (Viridian Therapeutics)? This is my company